CD274 and melanoma: Amongst the most studied to date are levels of PD-L1 and PD-1 in EVs, which have been associated with poor responsiveness to immune checkpoint inhibitor (ICI) therapy in advanced melanoma patients (n = 93), with higher PD-1 being specifically associated with poorer progression free survival (PFS) and overall survival (OS) [79].